NeuroPace (NASDAQ:NPCE) Posts Earnings Results, Beats Estimates By $0.07 EPS

NeuroPace (NASDAQ:NPCE) announced its earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07, Zacks reports. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.

NeuroPace Price Performance

NeuroPace stock traded up $0.11 during trading hours on Tuesday, reaching $11.92. 245,578 shares of the stock were exchanged, compared to its average volume of 119,388. The stock has a 50 day moving average of $12.70 and a two-hundred day moving average of $9.71. The company has a market cap of $355.79 million, a P/E ratio of -11.92 and a beta of 2.05. NeuroPace has a twelve month low of $5.45 and a twelve month high of $16.34. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. UBS Group initiated coverage on NeuroPace in a report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price target on the stock. JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Finally, Wells Fargo & Company upped their price objective on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $14.80.

Insider Activity

In related news, insider Martha Morrell sold 3,200 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $15.01, for a total value of $48,032.00. Following the completion of the sale, the insider now directly owns 87,062 shares in the company, valued at $1,306,800.62. This represents a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total transaction of $49,545,943.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,352,479 shares of company stock worth $50,670,217. Insiders own 22.20% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.